Investor Information
| Stéphane Bette, Co founder and Deputy CEO |
Pierre Jérôme, Co founder, CEO & Chairman |
Dear Shareholders,
Take a look back at the capital increase with shareholders’ preferential subscription rights. View the management message
Read the latest Financial News
Stock Information
Stock exchange information
- ISIN code: FR0011464452
- Stock Quote: ALSGD
- Number of shares: 53.501.768
- Sector: Medical technologies
- Principal Index: Alternext All-share
- Exchange: Euronext-Growth
- Place of listing: Euronext Paris (France)
- Eligibility to French PEA/SRD: Yes/No
- Eligibility French PEA-PME: Yes
Financial agenda
- 10 January 2024: 2023 Full-Year Sales
- 17 April 2024: 2023 Full-Year Results
- 17 April 2024: 2024 First-Quarter Sales
- 5 June 2024: Annual Shareholders Meeting (1st summoning)
- 26 June 2024: Annual Shareholders Meeting (2nd summoning if required)
- 15 July 2024: 2024 First-Half Sales
- 11 September 2024: 2024 First-Half Results
- 09 October 2024: 2024 Third-Quarter Sales
Analysts
- Biostrategic Research: Lionel Labourdette
Others
- Liquidity contract: Tradition Securities And Futures (TSAF)
- Auditors: Grant Thornton
- Listing Sponsor: Swiss Life Banque Privée
Shareholders structure
(June 7th, 2024)
Stock quotes
- To check the stock quote in real time, click here
For any request, don't hesitate to contact us